PTPI Stock Overview
A pharmaceutical company, focuses on men’s health therapeutics in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Petros Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.36 |
| 52 Week High | US$2.27 |
| 52 Week Low | US$0.22 |
| Beta | 1.94 |
| 1 Month Change | 0.83% |
| 3 Month Change | 8.69% |
| 1 Year Change | -73.43% |
| 3 Year Change | -98.64% |
| 5 Year Change | n/a |
| Change since IPO | -99.09% |
Recent News & Updates
Recent updates
It's Probably Less Likely That Petros Pharmaceuticals, Inc.'s (NASDAQ:PTPI) CEO Will See A Huge Pay Rise This Year
Nov 13
Petros Pharmaceuticals GAAP EPS of -$0.10, revenue of $6.6M
Aug 15Petros Pharma shares more than triple in value after co to be taken private in $67.2M deal
Jul 28Petros Pharmaceuticals: Advancing Complementary Men's Health Therapeutics
Dec 07Shareholder Returns
| PTPI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -7.6% | 0.5% | 0.7% |
| 1Y | -73.4% | 2.2% | 23.0% |
Return vs Industry: PTPI underperformed the US Pharmaceuticals industry which returned 2.8% over the past year.
Return vs Market: PTPI underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| PTPI volatility | |
|---|---|
| PTPI Average Weekly Movement | 31.9% |
| Pharmaceuticals Industry Average Movement | 10.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PTPI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PTPI's weekly volatility has increased from 19% to 32% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 21 | Fady Boctor | www.petrospharma.com |
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men’s health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).
Petros Pharmaceuticals, Inc. Fundamentals Summary
| PTPI fundamental statistics | |
|---|---|
| Market cap | US$4.11m |
| Earnings (TTM) | -US$19.85m |
| Revenue (TTM) | US$4.02m |
0.9x
P/S Ratio-0.2x
P/E RatioIs PTPI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PTPI income statement (TTM) | |
|---|---|
| Revenue | US$4.02m |
| Cost of Revenue | US$1.11m |
| Gross Profit | US$2.92m |
| Other Expenses | US$22.76m |
| Earnings | -US$19.85m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.98 |
| Gross Margin | 72.50% |
| Net Profit Margin | -493.45% |
| Debt/Equity Ratio | 232.5% |
How did PTPI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 10:47 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Petros Pharmaceuticals, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nazibur Rahman | Maxim Group |